NANT Clinical Trials

The NANT Consortium performs clinical trials that test new ways to treat high-risk neuroblastoma. NANT Consortium clinical trials focus on therapies to treat those patients with neuroblastoma that no longer responds to chemotherapy, radiation or retinoic acid. Most NANT clinical trials are Phase I studies. If you are interested in participating in or referring a patient for participation in a NANT study, contact a NANT Consortium institution or the NANT Operations Center.

What are phase I Clinical Trials:

These are the first studies that test new treatments in people after they have shown promise in laboratory studies. The main purpose of these types of studies is to find out what dose is safe and what side effects are caused by the therapy. These studies enroll a few patients at a time at gradually increasing doses. Studies may stop entering new patients for a short time while the prior group of patients is evaluated for side effects.

Current NANT Consortium Clinical Trials that are entering patients:

Click to get more information about each trial:

• N99-02: Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) (NSC-326321) and Autologous Stem Cell Support For Recurrent High-Risk Neuroblastoma (NCI 68).
• N2001-02: A Phase II study of 131I-Metaiodobenzylguanidine (MIBG) with Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma.
• N2001-03: A Phase I study of CEP-701 in Patients with Refractory Neuroblastoma.
• N2004-03: A Phase I study of intravenous fenretinide in pediatric neuroblastoma.
• N2004-04: A Phase I Study of Fenretinide Lym-X-Sorb^TM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68,254)
• N2004-06: Irinotecan and Vincristine with ¹³¹I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma